ArticleCancer management and research2020
Predictive Factors for Level V Lymph Node Metastases in Papillary Thyroid Carcinoma with
Article in Cancer management and research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- Preoperative Co-Mutation of BRAFCancer medicine · 2026Article
- Superior prognostic performance of modified N staging incorporating N1c in papillary thyroid carcinoma.Scientific reports · 2026Article
- Patterns of Lateral Lymph Node Involvement by Neck Level in cNIb Differentiated Thyroid Carcinoma: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2025Review
- Is it possible to rule out level II and level VB dissection in patients with metastatic papillary thyroid cancer?Frontiers in endocrinology · 2025Article
- BRAF V600E mutation in thyroid carcinoma: a large-scale study in Han Chinese population.World journal of surgical oncology · 2024Article
- Surgical Complications in Papillary Thyroid Cancer Patients with Cervical Lymph Node Metastases.Clinical Medicine Insights. Oncology · 2024Article
- Risk factors for level V metastasis in patients with N1b papillary thyroid cancer.World journal of surgical oncology · 2022Article
- A Prediction Model for Contralateral Central Neck Lymph Node Metastases in Unilateral Papillary Thyroid Cancer.International journal of endocrinology · 2021Article
- BRAF V600E and lymph node metastases in papillary thyroid cancer.Endocrine connections · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTherapeutic lateral neck dissection (LND) is recommended in papillary thyroid carcinoma (PTC) patients with clinically lateral lymph node metastasis (LLNM), whether underwent level V LND remains controversial for lacking of sensitive predicting system.
methodsUnivariate and multivariate analyses were retrospectively conducted on the potential predictive factors of 252 PTC patients who underwent initial treatment of neck lymph node dissection from September 2015 to October 2018 in our institute.
resultsLLNM was presented in 208 (82.5%) patients and level II-V LNM was present in 42.8%, 71.2%, 85.1%, 17.8% patients, respectively.
conclusionIn summary, we presented several independent predictive factors for level V LNM in PTC patients. We constructed a risk prediction model consisting of tumor size ≥2.5 cm, number of CLNM≥3 and level II metastases and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.